Nobivac Piro

Withdrawn

This medicine's authorisation has been withdrawn

vaccine against babesiosis in dogs

Overview

The marketing authorisation for Nobivac Piro has been withdrawn at the request of the marketing-authorisation holder.

Nobivac Piro : EPAR - Summary for the public

Product information

Nobivac Piro : EPAR - Product Information

Nobivac Piro : EPAR - All Authorised presentations

Product details

• Name of medicine:
  Nobivac Piro
• Active substance:
  • babesia canis, inactivated
  • babesia rossi, inactivated
• International non-proprietary name (INN) or common name:
  vaccine against babesiosis in dogs
• Species:
  Dogs
• Anatomical therapeutic chemical veterinary (ATCvet) code:
  QI07AO

Pharmacotherapeutic group

Immunologicals for canidae

Therapeutic indication

For active immunisation of dogs of six months of age or older against Babesia canis to reduce the severity of clinical signs associated with acute babesiosis (B. canis) and anaemia as measured by packed cell volume.

Onset of immunity: Three weeks after the basic vaccination course.

Duration of immunity: Six months after the last (re-)vaccination.

Authorisation details

• EMA product number:
  EMEA/V/C/000084
• Marketing authorisation holder:
  Intervet International BV

  Wim de Körverstraat 35; 5831 AN Boxmeer; The Netherlands

• Marketing authorisation issued:
  02/09/2004
• Revision:
  4

Assessment history

Changes since initial authorisation of medicine

Nobivac Piro : EPAR - Procedural steps taken and scientific information after authorisation

Initial marketing authorisation documents

Nobivac Piro : EPAR - Procedural steps taken before authorisation

Nobivac Piro : EPAR - Scientific Discussion